Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163635 | 0.90 | MET (0.64) | MET | |
| SCHEMBL1163319 | 0.90 | MET (0.64) | MET | |
| SCHEMBL9102946 | 0.87 | MET (1.00) | MET | |
| SCHEMBL9102938 | 0.87 | MET (1.00) | MET | |
| SCHEMBL6520604 | 0.86 | MET (1.00) | MET | |
| SCHEMBL6520600 | 0.86 | MET (1.00) | MET | |
| SCHEMBL9103813 | 0.86 | MET (1.00) | MET | |
| SCHEMBL9103818 | 0.86 | MET (1.00) | MET | |
| SCHEMBL9103797 | 0.86 | MET (1.00) | MET | |
| SCHEMBL29435059 | 0.86 | MET (1.00) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8497368-B2 | Heterocyclic hydrazone compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| WO-2011020861-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020861-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011018454-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018454-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION | NOVARTIS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142681-A1 | HETEROCYCLIC HYDRAZONE COMPOUNDS | MET, HGF, RET | MET 1/4885 |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | MET 1/4885 |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.